糖皮质激素治疗增加危重症期间胆固醇可用性:对肾上腺及肌肉功能的影响
该研究基于EPaNIC RCT中324例长期危重症患者的匹配集进行二次分析,评估糖皮质激素治疗与入ICU至第5天血浆胆固醇的关联;并在盲肠结扎穿孔诱导脓毒症小鼠模型中,将小鼠随机分为氢化可的松1.2 mg/天组(n=17)与安慰剂组(n=15)治疗5天,并与健康小鼠(n=18)比较。人类患者中,糖皮质激素治疗与自ICU第2天(HDL胆固醇)和第3天(LDL胆固醇)起至第5天较高的血浆HDL和LDL胆固醇相关(P<0.05)。脓毒症小鼠中,氢化可的松使血浆皮质酮不再升高,减轻脓毒症所致血浆HDL、LDL胆固醇及肾上腺皮质胆固醇下降(P<0.05),但未改善ACTH诱导的皮质酮反应,且肾上腺皮质炎症和凋亡增加(P<0.05);氢化可的松组总休质量进一步下降(P<0.01),瘦体质量及总水和游离水丢失增加(P<0.05),肌肉再生标志物受抑(P<0.05)。作者结论认为糖皮质激素部分减轻危重症诱导的低胆固醇血症,但代价是肾上腺功能受损、肌肉再生受抑和体质量丢失加重。
要点
- 在EPaNIC RCT的324例长期危重症患者中,糖皮质激素治疗与自ICU第2天起HDL胆固醇、第3天起LDL胆固醇升高相关,持续至第5天(P<0.05)。
- 脓毒症小鼠中,氢化可的松1.2 mg/天治疗5天使血浆皮质酮不再升高,并减轻脓毒症所致血浆HDL、LDL胆固醇及肾上腺皮质胆固醇下降(P<0.05)。
- 氢化可的松未改善脓毒症小鼠肾上腺皮质ACTH诱导的皮质酮反应,反而增加肾上腺皮质炎症和凋亡(P<0.05)。
- 氢化可的松组脓毒症小鼠总休质量进一步下降(P<0.01),瘦体质量及总水和游离水丢失增加(P<0.05),肌肉再生标志物受抑(P<0.05)。
- 氢化可的松对脓毒症小鼠肌肉质量、肌力或肌纤维大小无额外影响,也未改变肌肉萎缩和纤维化标志物的升高。
适用人群与场景
- 人类部分:EPaNIC RCT中324例长期危重症患者的匹配集,进行二次分析。
- 小鼠部分:盲肠结扎穿孔诱导脓毒症小鼠,随机接受氢化可的松(n=17)或安慰剂(n=15)治疗5天,并与健康小鼠(n=18)比较;另有一项相同设计的连续小鼠研究(n=24)用EchoMRI评估全身成分。
处置流程与药物剂量
- 小鼠脓毒症模型中氢化可的松剂量为1.2 mg/天,给药5天;人类患者中糖皮质激素的治疗方案未在本文中描述。
研究设计与关键结果
- 研究类型:EPaNIC RCT的二次分析(人类部分)及盲肠结扎穿孔脓毒症小鼠实验(动物部分)。
- 人类部分:糖皮质激素治疗与自ICU第2天起较高的血浆HDL胆固醇、自第3天起较高的LDL胆固醇相关,持续至第5天(P<0.05)。
- 小鼠部分:氢化可的松组脓毒症小鼠血浆皮质酮不再高于安慰剂组,脓毒症所致血浆HDL、LDL胆固醇及肾上腺皮质胆固醇下降减轻(P<0.05)。
- 氢化可的松未改善肾上腺皮质ACTH诱导的皮质酮反应,且肾上腺皮质炎症和凋亡增加(P<0.05)。
- 氢化可的松组总休质量较安慰剂组进一步下降(P<0.01),对肌肉质量、肌力或肌纤维大小无额外影响。
- 氢化可的松未改变脓毒症所致肌肉萎缩和纤维化标志物升高,但肌肉再生标志物较安慰剂组受抑(P<0.05)。
- 氢化可的松组瘦体质量及总水和游离水丢失较安慰剂组增加(P<0.05)。
证据类型、等级与局限
- 证据类型:随机对照试验(EPaNIC RCT)的二次分析及动物实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,糖皮质激素治疗部分减轻危重症诱导的低胆固醇血症,但代价是肾上腺功能受损、肌肉再生受抑和体质量丢失加重。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hypocholesterolemia hallmarks critical illness though the underlying pathophysiology is incompletely understood. As low circulating cholesterol levels could partly be due to an increased conversion to cortisol/corticosterone, we hypothesized that glucocorticoid treatment, via reduced de novo adrenal cortisol/corticosterone synthesis, might improve cholesterol availability and as such affect adrenal gland and skeletal muscle function.
METHODS: In a matched set of prolonged critically ill patients (n = 324) included in the EPaNIC RCT, a secondary analysis was performed to assess the association between glucocorticoid treatment and plasma cholesterol from ICU admission to day five. Next, in a mouse model of cecal ligation and puncture-induced sepsis, septic mice were randomized to receive either hydrocortisone (1.2 mg/day) (n = 17) or placebo (n = 15) for 5 days, as compared with healthy mice (n = 18). Plasma corticosterone, cholesterol, and adrenocortical and myofiber cholesterol were quantified. Adrenal structure and steroidogenic capacity were evaluated. Muscle force and markers of atrophy, fibrosis and regeneration were quantified. In a consecutive mouse study with identical design (n = 24), whole body composition was assessed by EchoMRI to investigate impact on lean mass, fat mass, total and free water.
RESULTS: In human patients, glucocorticoid treatment was associated with higher plasma HDL- and LDL-cholesterol from respectively ICU day two and day three, up to day five (P < 0.05). Plasma corticosterone was no longer elevated in hydrocortisone-treated septic mice compared to placebo, whereas the sepsis-induced reduction in plasma HDL- and LDL-cholesterol and in adrenocortical cholesterol was attenuated (P < 0.05), but without improving the adrenocortical ACTH-induced CORT response and with increased adrenocortical inflammation and apoptosis (P < 0.05). Total body mass was further decreased in hydrocortisone-treated septic mice (P < 0.01) compared to placebo, with no additional effect on muscle mass, force or myofiber size. The sepsis-induced rise in markers of muscle atrophy and fibrosis was unaffected by hydrocortisone treatment, whereas markers of muscle regeneration were suppressed compared to placebo (P < 0.05). An increased loss of lean body mass and total and free water was observed in hydrocortisone-treated septic mice compared to placebo (P < 0.05).
CONCLUSIONS: Glucocorticoid treatment partially attenuated critical illness-induced hypocholesterolemia, but at a cost of impaired adrenal function, suppressed muscle regeneration and exacerbated loss of body mass.
参考来源
- De Bruyn L, Téblick A, Van Oudenhove T, et al. Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function. Crit Care. 2024. PMID: 39238038. doi:10.1186/s13054-024-05079-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。